NASDAQ:QTTB Q32 Bio Q2 2024 Earnings Report $15.56 +0.92 (+6.28%) Closing price 04:00 PM EasternExtended Trading$15.62 +0.06 (+0.39%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Q32 Bio EPS ResultsActual EPS-$1.42Consensus EPS -$1.00Beat/MissMissed by -$0.42One Year Ago EPSN/AQ32 Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AQ32 Bio Announcement DetailsQuarterQ2 2024Date8/8/2024TimeN/AConference Call DateThursday, August 8, 2024Conference Call Time7:15AM ETUpcoming EarningsQ32 Bio's Q2 2026 earnings is estimated for Wednesday, August 5, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, August 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Q32 Bio Earnings HeadlinesHC Wainwright Raises Q32 Bio (NASDAQ:QTTB) Price Target to $36.00July 30 at 1:24 AM | americanbankingnews.comRoivant Sciences (NASDAQ:ROIV) and Q32 Bio (NASDAQ:QTTB) Critical SurveyJuly 25, 2026 | americanbankingnews.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.July 30 at 1:00 AM | Stansberry Research (Ad)Q32 Bio: Bempikibart's Progress Keeps Me BullishJuly 17, 2026 | seekingalpha.comQ32 Bio prices $200M equity raiseJuly 15, 2026 | msn.comQ32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded WarrantsJuly 14, 2026 | prnewswire.comSee More Q32 Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Q32 Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Q32 Bio and other key companies, straight to your email. Email Address About Q32 BioQ32 Bio (NASDAQ:QTTB), a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.View Q32 Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Microsoft Just Flipped the AI Spending Narrative OvernightQualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?Can Starbucks Keep This Turnaround Going? The Latest Results Say YesTesla: After a Rough Quarter, 2 Very Different Futures Come Into FocusMeta’s Earnings Show Why Wall Street Is Losing Patience With AI SpendingWhy NXP Semiconductors Could Be the AI Stock Everyone Is MissingPalantir’s Earnings Setup Puts Its AI Growth Story Back on Trial Again Upcoming Earnings Linde (7/31/2026)Keysight Technologies (7/31/2026)Colgate-Palmolive (7/31/2026)Chevron (7/31/2026)Enbridge (7/31/2026)ExxonMobil (7/31/2026)NatWest Group (7/31/2026)Sumitomo Mitsui Financial Group (7/31/2026)Eaton (7/31/2026)AbbVie (7/31/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
